AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development

• Published in: The AAPS journal Vol. 13; no. 3; pp. 405 - 416
• Main Authors: Girish, Sandhya, Martin, Steven W, Peterson, Mark C, Zhang, Lei K., Zhao, Hong, Balthasar, Joseph, Evers, Raymond, Zhou, Honghui, Zhu, Min, Klunk, Lewis, Han, Chao, Berglund, Eva Gil, Huang, Shiew-Mei, Joshi, Amita
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.09.2011
• Subjects: Biochemistry; Biomedical and Life Sciences; Biomedicine; Biotechnology; Clinical Trials as Topic; Drug Discovery - methods; Drug Industry - methods; Drug Industry - standards; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Meeting Report; Pharmacology/Toxicology; Pharmacy; Proteins - adverse effects; question based; drug interactions; therapeutic proteins; regulatory; risk based
• ISSN: 1550-7416; 1550-7416
• DOI: 10.1208/s12248-011-9285-6

Therapeutic proteins (TPs) are increasingly combined with small molecules and/or with other TPs. However preclinical tools and in vitro test systems for assessing drug interaction potential of TPs such as monoclonal antibodies, cytokines and cytokine modulators are limited. Published data suggests that clinically relevant TP-drug interactions (TP-DI) are likely from overlap in mechanisms of action, alteration in target and/or drug-disease interaction. Clinical drug interaction studies are not routinely conducted for TPs because of the logistical constraints in study design to address pharmacokinetic (PK)- and pharmacodynamic (PD)-based interactions. Different pharmaceutical companies have developed their respective question- and/or risk-based approaches for TP-DI based on the TP mechanism of action as well as patient population. During the workshop both company strategies and regulatory perspectives were discussed in depth using case studies; knowledge gaps and best practices were subsequently identified and discussed. Understanding the functional role of target, target expression and their downstream consequences were identified as important for assessing the potential for a TP-DI. Therefore, a question-and/or risk-based approach based upon the mechanism of action and patient population was proposed as a reasonable TP-DI strategy. This field continues to evolve as companies generate additional preclinical and clinical data to improve their understanding of possible mechanisms for drug interactions. Regulatory agencies are in the process of updating their recommendations to sponsors regarding the conduct of in vitro and in vivo interaction studies for new drug applications (NDAs) and biologics license applications (BLAs).